Recombinant Human Plasma Gelsolin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Recombinant Human Plasma Gelsolin
Accession Number
DB15746
Description

Plasma gelsolin (pGSN) is a protein found in the blood of healthy individuals which scavenges compounds left over from damaged tissues.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Recombinant Enzymes
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • pGSN
  • Plasma gelsolin
  • Rhu-pGSN
External IDs
  • Recombinant Human Plasma Gelsolin

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action

pGSN also enhances bacterial uptake and death by macrophages. It has positive effects on the immune system as it boosts clearing of pathogens and modulates inflammatory reactions; often pGSN is consumed in both serious infectious and non-infectious conditions. Its physiological effects thus make it a potential candidate for severe acute respiratory syndrome (ARDS) associated with COVID-19, as administration of recombinant protein is thought to supplement depleted levels of pGSN.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Tannous A, Levinson SL, Bolognese J, Opal SM, DiNubile MJ: Safety and Pharmacokinetics of Recombinant Human Plasma Gelsolin in Patients Hospitalized for Non-Severe Community-Acquired Pneumonia. Antimicrob Agents Chemother. 2020 Jul 20. pii: AAC.00579-20. doi: 10.1128/AAC.00579-20. [PubMed:32690640]
  2. Piktel E, Wnorowska U, Ciesluk M, Deptula P, Prasad SV, Krol G, Durnas B, Namiot A, Markiewicz KH, Niemirowicz-Laskowska K, Wilczewska AZ, Janmey PA, Reszec J, Bucki R: Recombinant Human Plasma Gelsolin Stimulates Phagocytosis while Diminishing Excessive Inflammatory Responses in Mice with Pseudomonas aeruginosa Sepsis. Int J Mol Sci. 2020 Apr 7;21(7). pii: ijms21072551. doi: 10.3390/ijms21072551. [PubMed:32272559]
  3. Yang Z, Bedugnis A, Levinson S, Dinubile M, Stossel T, Lu Q, Kobzik L: Delayed Administration of Recombinant Plasma Gelsolin Improves Survival in a Murine Model of Penicillin-Susceptible and Penicillin-Resistant Pneumococcal Pneumonia. J Infect Dis. 2019 Sep 26;220(9):1498-1502. doi: 10.1093/infdis/jiz353. [PubMed:31287867]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19)1
1, 2CompletedTreatmentBurned / Infection / Low Gelsolin / Traumas1
1, 2CompletedTreatmentCommunity Acquired Pneumonia (CAP)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on August 11, 2020 15:27 / Updated on August 13, 2020 01:02

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates